Modality
Bispecific Ab
MOA
MALT1i
Target
FLT3
Pathway
PD-1/PD-L1
Schizophrenia
Development Pipeline
Preclinical
~Aug 2020
→ ~Nov 2021
Phase 1
~Feb 2022
→ ~May 2023
Phase 2
Aug 2023
→ Dec 2031
Phase 2Current
NCT03055309
2,380 pts·Schizophrenia
2023-08→2031-12·Active
2,380 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-06-233mo awayEnrollment Complete· Schizophrenia
2031-12-105.7y awayPh2 Data· Schizophrenia
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Active
Catalysts
Enrollment Complete
2026-06-23 · 3mo away
Schizophrenia
Ph2 Data
2031-12-10 · 5.7y away
Schizophrenia
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03055309 | Phase 2 | Schizophrenia | Active | 2380 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| ITC-6153 | Intra-Cellular | Phase 3 | KRASG12C | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 |